| Similar Articles |
|---|
 |
The Motley Fool
December 27, 2010
Dan Dzombak |
3 Watchlist Stocks Lloyds, Transocean, and Mosaic -- oh my!   |
The Motley Fool
January 31, 2011
Dan Dzombak |
5 Small-Cap Stocks on Fire These five watchlist stocks have been on fire lately: Capstone Turbine... Avanir Pharmaceuticals... Power-One... Oilsands Quest... FuelCell Energy... |
The Motley Fool
March 1, 2011
Dan Dzombak |
Deepwater Experience Pays Off ATP Oil & Gas announces it has acquired 40%-50% ownership of five licenses (pending government approval) in Israel's Levantine Basin. |
The Motley Fool
October 12, 2010
Travis Hoium |
ATPG Shares Popped: What You Need to Know ATP Oil & Gas shares jumped 10% in intraday trading, on news that the Obama administration is lifting the deepwater drilling ban. |
The Motley Fool
September 20, 2010
Jordan DiPietro |
Why Did These Stocks Plunge? Let's look at some stocks that plunged on Friday, and examine whether any logic justified their shift |
The Motley Fool
May 27, 2011
Brian Orelli |
Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug. |
The Motley Fool
March 18, 2008
Brian Orelli |
Lack of Side Effects Doesn't Fatten Arena Good safety data on its obesity drug fails to plump up Arena's stock price. Investors, take note. |
The Motley Fool
December 22, 2010
Matt Koppenheffer |
Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume. |
The Motley Fool
September 2, 2010
Brian Orelli |
Fatter Wallet. Up 22%. Still Risky. After VIVUS' Qnexa was shot down at its FDA advisory panel, it's clear that Arena and Orexigen have an uphill battle in front of them. |
The Motley Fool
March 7, 2011
Sean Williams |
ATP Oil & Gas: Bargain Buy or Value Trap? See which proves triumphant: its oil reserves or its mountain of debt. |
The Motley Fool
September 14, 2010
Brian Orelli |
42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason. |
The Motley Fool
October 25, 2010
Brian Orelli |
Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know. |
The Motley Fool
October 11, 2010
Brian Orelli |
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... |
The Motley Fool
June 16, 2011
Isac Simon |
Why ATP Oil & Gas Is a Buy Right Now With new assets acquired offshore Israel and a massive opportunity sitting in the Gulf, the future looks very promising for ATP. |
The Motley Fool
January 28, 2011
Brian Orelli |
Arena's Obese To-Do List The Food and Drug Administration's laundry list for Arena Pharmaceuticals seems to be getting longer. |
The Motley Fool
March 21, 2011
Dan Dzombak |
This Stock Is a Double-Bagger ATP Oil & Gas doubled over the past nine months and it may do it again. |
The Motley Fool
July 13, 2010
Brian Orelli |
A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight. |
The Motley Fool
July 2, 2010
Brian Orelli |
Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get? |
The Motley Fool
July 16, 2010
Jordan DiPietro |
Why Did These Stocks Plunge? A look at the prior day's biggest losers: Orexigen... Arena Pharmaceuticals... DragonWave... |
The Motley Fool
September 17, 2010
Brian Orelli |
Thanks for Nothing, Fen-Phen Arena gets knocked down despite a relatively clean side-effect profile. |
The Motley Fool
March 30, 2011
Brian Orelli |
This Share Count Might Need Some Obesity Meds Soon Arena gets some dilutive financing. |
The Motley Fool
December 22, 2010
Brian Orelli |
Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is. |
The Motley Fool
September 16, 2010
Brian Orelli |
Abbott's Product Line May Get Thinner Not that it needs the obesity drug. |
The Motley Fool
January 19, 2011
Dan Dzombak |
Rising Stars Buy: ATP Oil & Gas This energy company buys proven, yet undeveloped, offshore fields and brings them into production. |
The Motley Fool
September 18, 2009
Brian Orelli |
Up, Down, Up. Is This Stock a Home Run or Not? Shares of Arena Pharmaceuticals have been on a roller coaster after word that the company would release data for its obesity drug. |
The Motley Fool
March 30, 2009
Brian Orelli |
Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration. |
The Motley Fool
June 23, 2010
Kris Eddy |
Not all Energy Stocks Are the Same Don't let the disaster in the Gulf scare you from energy stocks. |
The Motley Fool
December 3, 2010
Brian Orelli |
Obesity Drug Companies Are (Still) Risky Orexigen heads before an FDA panel. |
The Motley Fool
September 21, 2010
Brian Orelli |
Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out. |
The Motley Fool
July 16, 2010
Brian Orelli |
Why VIVUS Is 57% Thinner In a move that slashed the pharmaceutical's shares, Food and Drug Administration advisory committee recommended that the agency not approve their obesity drug Qnexa. |
The Motley Fool
December 29, 2010
Toby Shute |
Looking Back at a Stock Pick That Stunk Today we're going to take a look at a stock that was supposed to set the world on fire in 2010, but didn't. That would be my selection of ATP Oil & Gas for our Best Stocks for 2010 series. |
The Motley Fool
September 29, 2010
Toby Shute |
A Big Piece Falls Into Place for ATP This offshore producer's latest financial move was essential to securing its future. |
The Motley Fool
August 9, 2010
Jordan DiPietro |
5 Dirt-Cheap Energy Stocks Look at these highly rated stocks to find value. |
The Motley Fool
November 9, 2010
Brian Orelli |
Arena Pharmaceuticals Scores Some Points Overall, the recent Bloom-DM study leaves Arena in a slightly better position than it was in before the data was released, but this battle to get lorcaserin approved is far from over. |
The Motley Fool
June 10, 2011
David Lee Smith |
For Exxon and Noble, the Gulf's Going Good After being held at bay for nearly a year, Exxon's found some terrific lures. |
The Motley Fool
October 5, 2010
Jeremy Phillips |
Should You Sell ATP Oil & Gas Today? We're seeking danger signs among our most beloved stocks. |
The Motley Fool
January 5, 2011
David Lee Smith |
Drilling Will Get Going in the Gulf Thirteen companies get the OK to return to their Gulf of Mexico toils. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
January 4, 2012
Brian Orelli |
This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval. |
The Motley Fool
April 7, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: United States Natural Gas Fund... Arena Pharmaceuticals... |
The Motley Fool
November 1, 2011
Travis Hoium |
Independent Oil and Gas Stocks Plunged: What You Need to Know Shares of independent oil and gas companies ATP Oil & Gas, Petroleum Development, and Stone Energy all fell 10% today driven by the price of oil. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
October 13, 2010
Travis Hoium |
Hold the Applause for End of Drilling Ban Ending the moratorium lifts drilling shares, but there are new rules to follow. |
The Motley Fool
December 30, 2011
Brian Orelli |
Working Through the Obese To-Do List in 2011 Arena ends the year on an upswing. |
The Motley Fool
July 16, 2010
Luke Timmerman |
Vivus Obesity Drug Shot Down by FDA Panel Vivus suffered a setback today at an important meeting for the future of obesity drug development, with implications for Arena Pharmaceuticals and Orexigen Therapeutics. |
The Motley Fool
December 8, 2010
Brian Orelli |
Up 100% With Room to Fly Orexigen gets a positive FDA panel nod. |
The Motley Fool
October 3, 2008
Brian Orelli |
Merck Can't Fight the Munchies The pharma gives up on its anti-obesity drug. |
The Motley Fool
July 20, 2007
Brian Orelli |
Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit. |
The Motley Fool
April 15, 2010
Toby Shute |
Mr. Market Takes a Shine to My Top Stock Pick Now that shares are heading higher, let's revisit the value on offer. You may recall that in our Best Stocks for 2010 series, I made a pitch for ATP Oil & Gas. |
The Motley Fool
October 19, 2010
Brian Orelli |
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. |
